Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) traded down 1.4% on Thursday . The company traded as low as $50.20 and last traded at $50.51. 7,825,154 shares changed hands during trading, a decline of 67% from the average session volume of 23,662,002 shares. The stock had previously closed at $51.24.
Analysts Set New Price Targets
Several research firms recently weighed in on HIMS. Bank of America upped their price target on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research report on Tuesday, April 29th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Truist Financial set a $45.00 price target on shares of Hims & Hers Health in a report on Tuesday, June 24th. Finally, Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Saturday. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $39.58.
Read Our Latest Stock Report on Hims & Hers Health
Hims & Hers Health Price Performance
The stock has a market capitalization of $10.72 billion, a price-to-earnings ratio of 69.44, a PEG ratio of 1.76 and a beta of 2.02. The stock's 50 day simple moving average is $53.68 and its 200-day simple moving average is $41.14.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The business had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same quarter last year, the firm earned $0.05 EPS. Hims & Hers Health's revenue for the quarter was up 110.7% on a year-over-year basis. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,107 shares of the company's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the completion of the sale, the chief financial officer owned 63,222 shares of the company's stock, valued at $2,987,239.50. This represents a 26.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $58.40, for a total value of $7,482,616.80. Following the transaction, the chief executive officer owned 89,311 shares in the company, valued at approximately $5,215,762.40. This trade represents a 58.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 670,250 shares of company stock valued at $34,487,591 in the last three months. 17.71% of the stock is currently owned by corporate insiders.
Institutional Trading of Hims & Hers Health
A number of institutional investors and hedge funds have recently modified their holdings of HIMS. Webster Bank N. A. grew its stake in Hims & Hers Health by 229.1% in the 2nd quarter. Webster Bank N. A. now owns 905 shares of the company's stock valued at $45,000 after buying an additional 630 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health in the first quarter valued at about $30,000. Parallel Advisors LLC grew its position in shares of Hims & Hers Health by 175.0% in the second quarter. Parallel Advisors LLC now owns 1,155 shares of the company's stock valued at $58,000 after purchasing an additional 735 shares during the last quarter. UMB Bank n.a. increased its stake in shares of Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after purchasing an additional 933 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Hims & Hers Health during the 1st quarter worth about $41,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Further Reading
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
